clinical AI
The independent health system's new tech saves time on the scanning side while aiding physicians with better views of diagnostic images. The CIO discusses the benefits of this powerful system.
Mount Sinai Health System, Nvidia and ARC Innovation Center leaders describe how their collaboration aims to decode the human genome using AI in order to more precisely predict disease risk and understand individual therapy response.
Cleveland Clinic CIO Sarah Hatchett talks about how the health system is leveraging AI for use cases like clinical documentation, coding and sepsis detection to boost productivity for clinical and non-clinical staff.
Hal Wolf, HIMSS CEO, spotlights upcoming HIMSS26 presentations from Taiwan's China Medical University Hospital and South Korea's Samsung Medical Center, which will discuss AI-driven transformation and digital maturity.
Virginia Halsey of FDB explains how Model Context Protocols set limits for AI models so they defer to human clinical judgment rather than guessing at answers. This prevents hallucinations that can impact patient safety.
Shlomi Madar, CEO of SpotitEarly, discusses the company's noninvasive test using a breath sample, which is analyzed by specially trained dogs capable of identifying unique cancer-related scent signatures combined with AI technology.
Abhinav Shashank, Innovaccer CEO and cofounder, highlights the company's recently published manifesto, Autonomous Healthcare, and previews his upcoming HIMSS26 panel with other unicorn founders on tackling challenges in health tech.
CEO of Lirio, Marten den Haring, explains how the company uses its proprietary Large Behavior Model to understand a person’s health behaviors, motivations and decision-making patterns to drive personalized patient engagement in healthcare.
As medical practices seek to implement agentic AI, Michael Clark, OnPoint Healthcare Partners president, recommends constant oversight to ensure agents' work is repeatable, auditable and traceable by a clinical advisory team.
AION Labs CEO, Mati Gill, discusses the company’s extensive backing from pharma and tech giants to build AI startups, and how AION is looking beyond AI to explore quantum technologies for research and development in drug discovery.